AhR Structure and Canonical Signalling
The aryl hydrocarbon receptor (AhR, encoded by AHR gene) is a ligand-activated basic-region helix-loop-helix Per-Arnt-Sim (bHLH-PAS) transcription factor that heterodimerises with the aryl hydrocarbon nuclear translocator (ARNT, also HIF-1beta). In the cytoplasm, AhR is sequestered in a complex with chaperone proteins (HSP90, AIP/XAP2, CYP19A1). Ligand binding (endogenous: tryptophan metabolites like kynurenine, KYNA; exogenous: dioxins, PAHs, indoles) causes dissociation from chaperones and nuclear translocation. AhR-ARNT heterodimers bind xenobiotic response elements (XREs, consensus GCGTG) in target gene promoters to transactivate phase I detoxification genes CYP1A1/CYP1B1, phase II enzymes NQO1/GCLC, and immune modulators IL-22/IL-17/IL-10.
Endogenous Ligands: Tryptophan Metabolites
Tryptophan (Trp) is metabolised along multiple pathways that produce AhR ligands: (1) the kynurenine pathway (IDO1/TDO2→KYN→KYNA/QUIN) generates KYNA (kynurenic acid), a potent AhR ligand (Kd ~5 micromol/L); (2) the aryl hydrocarbon receptor agonist (AHSA) pathway generates indole derivatives from bacterial and plant Trp catabolism; (3) commensal bacteria produce indole, indole-3-aldehyde (I3A), and indole-3-propionic acid (IPA) via tryptophanase. KYNA, I3A, and IPA all activate AhR in the 5-50 micromol/L range. Spirulina indirectly increases KYNA through content of tryptophan (1.2 mg/100g DW) and through Nrf2-IDO1 induction in macrophages and dendritic cells, raising local KYNA and thus AhR activation in intestinal immune tissue.
AhR-Driven CYP1A1 and Phase I Detoxification
CYP1A1 (cytochrome P450 family 1 subfamily A member 1) catalyses the oxidative metabolism of polycyclic aromatic hydrocarbons (PAHs), heterocyclic amines, and other xenobiotics. AhR-ARNT binding to the XRE in the CYP1A1 promoter drives robust induction (10-100 fold) of CYP1A1 mRNA and protein. However, CYP1A1-catalysed oxidation of PAHs and heterocyclic amines generates reactive electrophilic intermediates (such as benzo[a]pyrene-7,8-dihydrodiol- 9,10-epoxide) that are pro-carcinogenic unless rapidly conjugated (phase II). Thus AhR activation is a double-edged sword: low-level KYNA activation of AhR promotes detoxification, but excessive environmental PAH/xenobiotic exposure coupled to AhR-CYP1A1 upregulation can overwhelm phase II capacity and increase mutagenesis. Balanced AhR signalling by moderate KYNA rather than chemical AhR agonists appears to minimise this risk.
AhR and IL-22/IL-17: Intestinal Barrier Function
AhR activation in intestinal intraepithelial lymphocytes (IELs) and group 3 innate lymphoid cells (ILC3s) drives IL-22 production. IL-22 signalling through IL-22R1 on epithelial cells activates STAT3, inducing antimicrobial peptides (REGIIIgamma/lysozyme), tight junction proteins (claudins, ZO-1/tjp1), and mucins (MUC2). Thus AhR-IL-22 axis is crucial for barrier integrity and mucosal immunity. Conversely, Th17 cells differentiate in response to IL-6+TGF-beta (STAT3) vs. IL-23 (STAT3 sustained); AhR activation in Th17 precursors promotes IL-22 over IL-17A production, skewing toward a protective IL-22-secreting ILC3 phenotype. Dysregulation of this balance (AhR deficiency or ligand starvation) leads to impaired IL-22, reduced REGIIIgamma, and increased pathogenic Th17, contributing to inflammatory bowel disease (IBD).
AhR, Foxp3, and Regulatory T Cell Differentiation
KYNA and other endogenous AhR ligands also promote Foxp3+ regulatory T cell (Treg) differentiation from naive Th0 cells in the presence of TGF-beta. AhR activation in Th0 cells enhances Foxp3 induction, IL-10 production, and Treg stability. This contrasts with the capacity of exogenous xenobiotic AhR ligands (TCDD, BaP) to promote pro-inflammatory Th17 responses. The distinction appears to depend on ligand identity and context: endogenous Trp metabolites promote tolerogenic IL-10/Foxp3, while high-dose environmental toxicants promote pro-inflammatory IL-17. Spirulina modulation of KYNA (via Nrf2-IDO1 induction) may thus bias intestinal immunity toward Treg-IL-10 balance.
AhR and Commensal Microbial Products
Commensal bacteria (particularly Lactobacillus, Bacteroides, and Faecalibacterium) produce indole-based metabolites via constitutive tryptophanase. Indole, I3A, and IPA are transported across the intestinal epithelium and activate AhR in immune cells and fibroblasts, promoting IL-22 and IL-10 production. Spirulina polysaccharides (Uronic acid, rhamnose-containing) and proteins act as prebiotics/probiotics, selectively supporting tryptophanase-containing commensals (Bacteroidetes, Firmicutes producers of IPA), increasing local indole metabolite availability and AhR activation. Thus spirulina has a tripartite effect on AhR: (1) direct Trp supply, (2) Nrf2-IDO1-driven KYNA, (3) prebiotic support of microbial tryptophanase.
Related Reading
Summary
The aryl hydrocarbon receptor acts as a molecular hub linking tryptophan catabolism, commensal microbial signalling, and intestinal immune balance. Spirulina engages this network by (1) supplying tryptophan precursor (~1.2 mg/100g), (2) activating Nrf2-IDO1 to increase endogenous KYNA, (3) prebiotic support of commensal tryptophanase-producers increasing indole metabolites (I3A/IPA), and (4) promoting microbial diversity that stabilises these AhR-ligand-producing taxa. The net result is sustained AhR-IL-22 axis activation, improved intestinal barrier function, and skewing of intestinal immunity toward protective IL-22+ILC3 and Foxp3+Treg phenotypes.